A central principle in cardiovascular disease (CVD) management is that the first lifetime diagnosis signals the failure of primary prevention and the need to initiate secondary prevention of recurrent or related CVD events. The decades-long emphasis given to prevention of myocardial infarction (MI) and stroke is reflected in remarkable declines – ≈33% over the past decade – in their incidence i...

BACKGROUND Once-daily low-dose aspirin is routinely used for the prevention of secondary events in cardiovascular disease (CVD). The routine use of aspirin in primary prevention of CVD is less clear due to a finer balance between benefits and harms. In addition, the variability in benefit achievable from the prescription of aspirin has led to a growing interest in considering whether there are ...

C ardiovascular diseases (CVD) represent the leading cause of morbidity and mortality worldwide. Prevention of CVD is an essential strategy for reducing the incidence of these conditions. Recent years have seen a decrease in heart disease mortality that was associated with changes in risk factors and improved treatment.1 Aspirin was considered the drug most widely used in the last century.2 It ...

BACKGROUND Coronary heart disease and cerebrovascular disease are leading causes of death in the United States. In 2002, the U.S. Preventive Services Task Force (USPSTF) strongly recommended that clinicians discuss aspirin with adults who are at increased risk for coronary heart disease. PURPOSE To determine the benefits and harms of taking aspirin for the primary prevention of myocardial inf...

Dear Sir The International Atherosclerosis Society (IAS) recently released harmonized guidelines for prevention of atheroscle-rotic disease through clinical management. 1 These guidelines integrate and harmonize existing guidelines for this purpose. Thanks to a large number of clinical trials, it is now possible to provide strong evidence-based guidelines for risk factor modification to prevent...

This is the protocol for a review and there is no abstract. The objectives are as follows: The primary objective is to determine the effectiveness of selenium only supplementation for the primary prevention of CVD. We will also determine potential adverse effects of selenium only supplementation on major CVD risk factors, such as blood pressure, blood lipids and type 2 diabetes. Results will be...

Cardiovascular diseases (CVDs) continue to be major contributors of death and disability globally. Control of CVD risk factors has been shown to be effective in reducing morbidity and mortality both in primary and secondary prevention settings. Given the cumulative benefits of concurrently controlling multiple CVD risk factors (high blood pressure, dyslipidemia and platelet activity) in individ...

AIMS To analyse the treatment and control of dyslipidaemia in patients at high and very high cardiovascular risk being treated for the primary prevention of cardiovascular disease (CVD) in Europe. METHODS AND RESULTS Data were assessed from the European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (EURIKA, ClinicalTrials.gov identifier: NCT00882336), which in...

INTRODUCTION In Poland, the National Health Fund (NHF) has contracted preventative interventions in primary health care (PHC) delivered by family physicians, internists, paediatricians and other physicians. The aim of the study was determining whether there is a correlation between PHC physicians' specialisation and the rate of interventions delivered for the prevention of cardiovascular diseas...

Cardiovascular diseases (CVD) are leading causes of premature mortality in India. Evidence from developed countries shows that mortality from these can be substantially prevented using population-wide and individual-based strategies. Policy initiatives for control of CVD in India have been suggested but evidence of efficacy has emerged only recently. These initiatives can have immediate impact ...